Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

29,097 people played the daily Crossword recently. Can you solve it faster than others?29,097 people played the daily Crossword recently. Can you solve it faster than others?

Eli Lilly has been unable to secure an accelerated ... study and comparisons inevitably drawn between it and the CLARITY-AD study of Leqembi, which revealed a 27% reduction in cognitive decline ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Eli Lilly stock is trending lower in December, but an FDA decision will keep compounders from making tirzepatide. Is Lilly stock a buy? Does Bill Ackman Know Something Wall Street Doesn't?

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...